Sotorasib

• Background :

  It is well established that RAS mutations are responsible for more than 30% of human cancers. KRAS (G12C) is the most frequent mutation, found in lung and colon carcinomas. Recent studies uncovered a small molecule called AMG510 (Amgen), or Sotorasib, that inhibits the KRAS (G12C) -mediated signaling pathway by locking the KRAS conformation in the GDP-bound state. Compounds that block the nucleotide exchange (GDP to GTP) reaction in KRAS could lead to the inhibition of tumor cell proliferation in KRAS (G12C) -driven tumors.

• Description :

  Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors1,2.

• Purity :

  ≥ 90%

• Format :

  Powder.

• Solubility :

  Soluble in DMSO up to 50 mg/mL. In H20, up to 33.33 mg/mL.

• Molecular Formula :

  C30H30F2N6O3

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, stored under nitrogenIn solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

• Calculated Molecular Weight :

  560.59 Da

• CAS Number :

  2296729-00-3